Structure Therapeutics Inc. (GPCR) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 38 days, typically, give or take 9 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 9, 2026after close 40 8-K
Q2 FY2026Thu, Aug 6, 2026after close 37 8-K
Q1 FY2026Thu, May 7, 2026after close 37 8-K
Q4 FY2025Thu, Feb 26, 2026after close 57 8-K
Q3 FY2025Thu, Nov 6, 2025after close 37 8-K
Q2 FY2025Wed, Aug 6, 2025after close 37 8-K
Q1 FY2025Thu, May 8, 2025after close 38 8-K
Q4 FY2024Thu, Feb 27, 2025after close 58 8-K

What they guided beta

Q3 FY2026 "Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028" exhibit
Q3 FY2026 "Additional aleniglipron data expected in Q4 2026 from supplementary body composition, type 2 diabetes and SWITCH studies" exhibit
Q3 FY2026 "Reported Phase 1 SAD data for ACCG-2671 (oral small molecule amylin receptor agonist), demonstrating a ~6-day half-life and no serious adverse events; MAD clinical trial dosing underway, with topline data expected in 1H 2027" exhibit
Q3 FY2026 "Cash, cash equivalents and short-term investments of $1.2 billion as of September 30, 2026 expected to fund projected operations and key clinical milestones through 2028" exhibit
Q3 FY2026 "Topline data are expected in the second half of 2028." exhibit
Q2 FY2026 "Cash, cash equivalents and short-term investments of $1.3 billion as of June 30, 2026 expected to fund projected operations and key clinical milestones through 2028" exhibit
Q2 FY2026 "As an important component of this strategy, we are advancing ACCG-2671, our potentially first-in-class oral small molecule dual amylin and calcitonin receptor agonist and remain on track to report initial single ascending dose data and initiate a multiple ascending dose clinical trial in the third quarter." exhibit
Q2 FY2026 "Data are expected in Q3 2026." exhibit
Q2 FY2026 "Data are expected in Q4 2026." exhibit
Q2 FY2026 "Data are expected in Q4 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/GPCR
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/GPCR

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

GPCR earnings date badge

HTML

<a href="https://veritasdata.dev/company/GPCR/"><img src="https://veritasdata.dev/embed/GPCR.svg" alt="GPCR earnings date" width="240" height="56"></a>

Markdown

[![GPCR earnings date](https://veritasdata.dev/embed/GPCR.svg)](https://veritasdata.dev/company/GPCR/)

Script

<script async src="https://veritasdata.dev/embed/GPCR.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/GPCR"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.